Serra J E, Pombo V, Côrte-Real R, da Cunha S, Meliço-Silvestre A
Clínica de Doenças Infecciosas, Hospital da Universidade de Coimbra.
Acta Med Port. 1993 Jan;6(1):5-9.
A study was performed on 51 human immunodeficiency virus (HIV 1)-infected patients with a previous history of drug abuse. By the CDC staging system for HIV infection they were mainly in advanced stages of that infection, 67% were in IV-A and 8% in IV-C1. Patients were divided in two groups, one composed of 33 individuals who needed AZT therapy and the other of those who did not need that medication (18 patients). Between 3 and 18 months several parameters were assessed on 3 different occasions, according to standard techniques: red blood cells and platelet numeration, CD4 and CD8 cell counts, HIV antigen (p24 Ag), beta 2-microglobulin, high density serum lipoproteins (HDL), and anticardiolipin antibodies (ACA). In the patients treated with AZT the first bioserologic evaluation was performed before starting this therapy. Finally it was observed that p24 AG and ACA were present in 21% of the patients, all of them in advanced stages of HIV infection and under AZT therapy. A significant correlation was only found between CD4 counts and beta 2-microglobulin (R = 0.34; P = 0.0001).
对51名有药物滥用史的人类免疫缺陷病毒（HIV-1）感染患者进行了一项研究。根据美国疾病控制与预防中心（CDC）的HIV感染分期系统，他们主要处于该感染的晚期，67%处于IV-A期，8%处于IV-C1期。患者被分为两组，一组由33名需要接受齐多夫定（AZT）治疗的个体组成，另一组由不需要该药物治疗的患者（18名）组成。在3至18个月期间，根据标准技术在3个不同时间点评估了几个参数：红细胞和血小板计数、CD4和CD8细胞计数、HIV抗原（p24 Ag）、β2-微球蛋白、高密度血清脂蛋白（HDL）和抗心磷脂抗体（ACA）。在接受AZT治疗的患者中，首次生物血清学评估在开始该治疗前进行。最后观察到，21%的患者存在p24 Ag和ACA，他们均处于HIV感染晚期且正在接受AZT治疗。仅在CD4计数与β2-微球蛋白之间发现显著相关性（R = 0.34；P = 0.0001）。
